India to Launch First Approved Dengue Vaccine Qdenga in 2027
Qdenga (TAK-003), developed by Takeda Pharmaceutical Company, has become the first dengue vaccine to receive marketing authorisation in India, granted by the Central Drugs Standard Control Organisation (CDSCO) in July 2026 for individuals aged 4 to 60 years.
Dr Reddy's Laboratories has entered an exclusive agreement with Takeda to promote and distribute Qdenga in India's private market.
The vaccine is expected to become available in India in the first half of 2027, following completion of remaining regulatory and import processes.
Qdenga is administered as a two-dose regimen, three months apart, and has already been approved in 43 countries with more than 32 million doses distributed globally.
Live-Attenuated Tetravalent Vaccine Technology
Qdenga is a live-attenuated tetravalent vaccine, meaning it uses a weakened (attenuated) form of a live virus, engineered to provide protection against all four dengue virus serotypes (DENV-1, DENV-2, DENV-3 and DENV-4) simultaneously. It is built on a DENV-2 backbone, into which genetic material for the other three serotypes has been inserted (a chimeric vaccine design).
Key Details
- Dengue is caused by four distinct serotypes of the dengue virus (a flavivirus, transmitted by Aedes aegypti and Aedes albopictus mosquitoes); prior infection with one serotype does not protect against the others and can, through antibody-dependent enhancement (ADE), increase the severity of a subsequent infection with a different serotype — the core scientific challenge in dengue vaccine design.
- A tetravalent design (covering all four serotypes at once) is intended to avoid the ADE risk that undermined an earlier dengue vaccine, Dengvaxia (Sanofi's CYD-TDV), which was found to increase severe-dengue risk in people who had not been previously infected (seronegative individuals).
- Live-attenuated vaccines generally produce durable, broad immune responses (as with the measles or yellow fever vaccines) but require careful safety evaluation in never-before-infected populations, which is why age-band restrictions (4-60 years here) and monitoring are typically applied at launch.
The reason Qdenga is being positioned as India's first approved dengue vaccine, rather than simply the first available one, is precisely because its tetravalent design was evaluated to avoid the ADE-related safety failure that limited the earlier Dengvaxia vaccine's use.
India's Dengue Burden and the National Vector Borne Disease Control Programme
Dengue is a notifiable vector-borne disease in India, monitored under the National Center for Vector Borne Diseases Control (NCVBDC) — formerly the National Vector Borne Disease Control Programme (NVBDCP) — under the Ministry of Health and Family Welfare, which tracks annual case counts, deaths and state-wise hotspots and coordinates vector-control measures such as source reduction and larvicide use.
Key Details
- Dengue transmission in India peaks during and after the monsoon season, when standing water increases Aedes mosquito breeding; states such as West Bengal, Kerala, Karnataka, Maharashtra and Delhi have historically reported high case burdens.
- Until Qdenga's approval, India had no licensed dengue vaccine; disease control relied entirely on vector management (Integrated Vector Management), clinical case management, and public awareness, with no vaccine-based prevention tool available domestically.
- Dengue case counts in India have shown a rising trend in recent years amid changing climatic and urbanisation patterns that favour mosquito breeding, reinforcing government emphasis on preventive tools such as vaccination alongside vector control.
Qdenga's approval and planned 2027 launch marks a shift from a purely vector-control-based national dengue strategy to one that, for the first time, adds a licensed vaccine as an additional (currently private-market) prevention layer within the broader disease-control framework overseen by the NCVBDC.
Drug and Vaccine Regulation: Role of CDSCO
The Central Drugs Standard Control Organisation (CDSCO), headed by the Drugs Controller General of India (DCGI), is India's central drug regulatory authority under the Ministry of Health and Family Welfare, responsible for approving new drugs and vaccines, conducting clinical trials oversight, and issuing manufacturing/import licences under the New Drugs and Clinical Trials Rules, 2019 (framed under the Drugs and Cosmetics Act, 1940).
Key Details
- Marketing authorisation from CDSCO is a mandatory prerequisite before any new vaccine can be legally sold or administered in India, whether manufactured domestically or imported.
- CDSCO's approval of Qdenga (July 2026) for the 4-60 age group is distinct from the subsequent commercial steps (import licensing, pricing, distribution tie-ups such as the Dr Reddy's-Takeda agreement) that determine when a vaccine actually becomes available to the public — explaining the roughly year-long gap between approval and the anticipated 2027 market launch.
- Since Qdenga would initially be a privately marketed vaccine (not yet part of India's Universal Immunisation Programme), its inclusion in any future public health programme would require a separate policy decision, typically informed by recommendations of the National Technical Advisory Group on Immunization (NTAGI).
The distinction between CDSCO's regulatory approval (already granted) and actual market availability (targeted for 2027) illustrates the multi-stage pathway — regulatory clearance, import/manufacturing scale-up, and commercial distribution — that separates a drug's approval from its public accessibility in India.
- Qdenga (TAK-003): live-attenuated tetravalent dengue vaccine, developed by Takeda Pharmaceutical Company.
- CDSCO marketing authorisation: granted July 2026, for ages 4-60 years.
- Dosing: two doses, three months apart.
- Distribution: exclusive agreement between Dr Reddy's Laboratories and Takeda for India's private market.
- Anticipated India launch: first half of 2027.
- Global reach: approved in 43 countries; over 32 million doses distributed worldwide.
- Dengue is caused by four serotypes (DENV-1 to DENV-4), transmitted by Aedes aegypti and Aedes albopictus mosquitoes.
- Dengue monitoring in India is under the National Center for Vector Borne Diseases Control (NCVBDC), Ministry of Health and Family Welfare.